DECAPRYN
LOE ApproachingNDAORALTABLET
Approved
Apr 1948
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DECAPRYN is an oral small-molecule tablet approved in 1948 by Sanofi under NDA type. The indication and mechanism of action are not publicly detailed in available data. This legacy product represents a foundational pharmaceutical asset with decades of clinical use.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling smaller or stabilizing commercial teams focused on retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflects the mature, stable nature of this legacy product with minimal growth investment. Career roles focus on operational efficiency, risk management, and retention strategies rather than innovation or market expansion.
Brand ManagerCommercial Operations Manager
Worked on DECAPRYN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.